Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver

Journal of Hepatology

Volumn 26, Issue 3, 1997, Pages 455-461

  Fukuda, Ryo ^a   Ishimura, Norihisa ^a   Kushiyama, Yoshinori ^a   Moriyama, Nobuyuki ^a   Ishihara, Shunji ^a   Nagasawa, Sachiko ^a   Miyake, Tatsuya ^a   Niigaki, Misa ^a   Satoh, Shuichi ^a   Sakai, Shino ^a   Akagi, Shuji ^a   Watanabe, Makoto ^a   Fukumoto, Shiro ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

chronic hepatitis C; interferon therapy; interferon receptor mRNA

Indexed keywords

ALPHA INTERFERON; INTERFERON RECEPTOR; MESSENGER RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0031040773     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80407-2     Document Type: Article

References (39)

1. Magrin S, Graxi A, Fabiano C, et al. Serum hepatitis C virus (HCV)-RNA and response to alpha interferon in anti-HCV positive chronic hepatitis. J Med Virol. 38:1992;200-206.
2. Kanazawa Y, Hayashi N, Mita E, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology. 20:1994;1121-1130.
3. Yoshida K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha: relationship to genotype of hepatitis C virus. Hepatology. 14:1992;35-40.
4. Weiland O, Schvarcz R, Weijstal R, Norkran G, Fryden M. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alpha-2b: Swedish experience. J Hepatol. 11:1990;S57-S62. (suppl 19).
5. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology. 19:1994;1088-1094.
6. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstractural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 334:1996;77-81.
7. De Maeyer E, De Maeyer-Guignand J. Interferon and Other Regulatory Cytokines. 1988;115-133 John Wiley & Sons, New York.
8. Yonehara S, Yonehara-Takahashi M, Ishii A. Binding of human interferon alpha to cells of different sensitivities: studies with internally radiorabeled interferon retaining full biological activity. J Virol. 45:1983;1168-1171.
9. Zoon KC, Arnheimer H. Studies of the interferon receptors. Pharmacol Ther. 24:1984;259-278.
10. Kato T, Esumi M, Yamashita S, Abe K, Shikata T. Interferon-inducible gene expression in chimpanzee liver infected with hepatitis C virus. Virology. 190:1992;856-860.
11. Velazquez L, Fellous M, Stark GR, Pellefrini S. A protein kinase in the interferon alpha/beta signaling pathway. Cell. 24:1992;313-322.
12. Müller U, Steihoff U, Reis LF, et al. Functional roles of type I and type II interferons in antiviral defense. Science. 264:1994;1918-1921.
13. 125I-labeled human interferon alpha beta and gamma: comparative receptor-binding data. J Gen Virol. 66:1985;1149-1152.
14. Aguet M, Grobke M, Dreiding P. Various human interferon alpha subclasses cross-react with common receptors: their binding affinities correlate with their specific biological activities. Virology. 132:1984;211-216.
15. De Maeyer E, De Maeyer-Guignand J. Interferon and Other Regulatory Cytokines. 1988;91-113 John Wiley & Sons, New York.
16. vitro and during interferon therapy. J Clin Invest. 77:1986;1632-1638.
17. Gallo-Rayet N, Escher E. Adrenocorticotropin receptors in rat adrenal glomerulosa cells. Endocrinology. 117:1985;38-46.
18. De Maeyer E, De Maeyer-Guignand J. Interferon and Other Revelatory Cytokines. 1988;221-273 John Wiley & Sons, New York.
19. Ishimura N, Fukuda R, Fukumoto S. Relationship between the expression of interferon-alpha receptor mRNA and the histological progress of hepatitis C virus associated chronic liver diseases. J Gastroenterol Hepatol. 11:1996;712-717.
20. Degroote J, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet. ii:1968;626-628.
21. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
22. Fukuda R, Satoh S, Nguyen TX, et al. Expression of cytokine mRNA in the liver of chronic hepatitis C: comparison with chronic hepatitis B. J Gastroenterol. 31:1995;41-47.
23. Uzé G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon α receptor into mouse cells: cloning and expression of its cDNA. Cell. 60:1990;225-234.
24. Okamoto H, Sugiyama Y, Okada S, et al. Typing of hepatitis C virus by polymerase chain reaction with type specific primers; application to clinical surveys and tracing infectious sources. J Gen Virol. 73:1992;673-679.
25. Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology. 104:1993;877-883.
26. Pregibon D. Logistic regression diagnosis. Ann Statist. 9:1981;705-724.
27. Su L, Morgan PR, Harrison DL, Waseen A, Lane EB. Expression of keratin mRNAs and proteins in normal salivary epithelia and pleomorphic adenomas. J Pathol. 171:1993;173-181.
28. Novick D, Cohen B, Rubinstein M. The human interferon α/gb receptor: characterization and molecular cloning. Cell. 77:1994;391-400.
29. Affabris E, Romeo G, Belardelli F, Jemma C, Mechti N, Gresser I, Rossi GB. 2-5A synthetase activity does not increase in interferon-resistant Friend leukemia cell variants treated with α/β interferon despite the presence of high-affinity interferon receptor sites. Virology. 125:1983;508-512.
30. 125I-labeled mouse interferon to interferon resistant embryonal carcinoma cells in vitro. Virology. 114:1981;585-588.
31. Branca AA, Bagloni C. Down-regulation of the interferon receptor. J Biol Chem. 257:1982;13197-13200.
32. Evans T, Secher DD. kinetics of internalization and degradation of surface-bound interferon in human lymphoblastoid cells. EMBO J. 3:1984;2975-2978.
33. Greenway AL, Hertzog PJ, Devenish RJ, Dudley FJ, McMullen GL, Linnane AW. Immunolocalisation of interferon-alpha in hepatitis C patients and its correlation with response to interferon-alpha therapy. J Hepatol. 21:1994;842-852.
34. Roffi L, Colloredo G, Antonelli G, et al. Breakthrough during recombinant interferon alpha therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology. 21:1995;645-649.
35. Klippel JH, Carrete S, Preble S, Friedman RM, Grimeley PM. Serum alpha interferon and lymphocyte inclusions in systemic lupus erythematosus. Ann Rheum Dis. 44:1985;104-108.
36. Koziel MJ, Duddley D, Wong JT, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol. 149:1992;3339-3344.
37. Kita H, Moriyama T, Kaneko T, et al. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology. 18:1993;1039-1044.
38. Lörh HF, Schlaak JF, Gerken G, Fleisher B, Diens HP. Meyer zum Büschenfelde KH. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver. 14:1994;161-166.
39. Simonds P, Alberti A, Alter HJ, et al. A proposed systems for the nomenclature of hepatitis C viral genotype. Hepatology. 19:1994;1321-1324.